SAB Biotherapeutics, Inc. (NASDAQ:SABSW – Get Free Report) saw a large decline in short interest in April. As of April 30th, there was short interest totaling 339 shares, a decline of 73.4% from the April 15th total of 1,276 shares. Based on an average trading volume of 7,336 shares, the days-to-cover ratio is presently 0.0 days.
SAB Biotherapeutics Stock Performance
Shares of NASDAQ:SABSW traded up $0.00 during mid-day trading on Wednesday, hitting $0.02. The company had a trading volume of 18,039 shares, compared to its average volume of 22,259. The firm has a fifty day moving average price of $0.03 and a 200 day moving average price of $0.03. SAB Biotherapeutics has a one year low of $0.02 and a one year high of $0.18.
About SAB Biotherapeutics
SAB Biotherapeutics, Inc is a clinical-stage biopharmaceutical company specializing in the development of fully human polyclonal antibody therapeutics. The company’s core technology, known as the Transchromosomic (Tc) Bovine platform, leverages genetically engineered cattle to produce large volumes of human antibodies in response to targeted antigens. These antibodies are designed to treat a range of infectious diseases and immunological disorders, offering a complementary approach to monoclonal antibodies and traditional vaccines.
The company’s lead programs focus on combating high-priority pathogens, including emerging coronaviruses and other viral threats.
Further Reading
- Five stocks we like better than SAB Biotherapeutics
- D-Wave Earnings Looked Weak, But Investors May Be Missing This
- Nebius Upside Expands as AI Feedback Loop Intensifies
- Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell
- Plug Power Flips The Switch On Profitability
Receive News & Ratings for SAB Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAB Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
